Psoriasis patient preferences for topical drugs: a systematic review

References

• Palota T, Szepietowski JC, Pec J, et al. A survey of disease severity, quality of life, and treatment patterns of biologically naive patients with psoriasis in central and eastern Europe. Acta Dermatovenerologica Croatica. 2010;18(3):151–162.
   PubMed Web of Science ®Google Scholar
• Schmid-Ott G, Schallmayer S, Calliess IT. Quality of life in patients with psoriasis and psoriasis arthritis with a special focus on stigmatization experience. Clin Dermatol. 2007;25(6):547–554.
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Richards HL. Psychological influences in psoriasis. Clin Exp Dermatol. 2001;26(4):338–342.
   PubMed Web of Science ®Google Scholar
• Kurd SK, Troxel AB, Crits-Christoph P, et al. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146(8):891–895.
   PubMed Web of Science ®Google Scholar
• Warren RB, Griffiths C. Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine. Clin Dermatol. 2008;26(5):438–447.
   PubMed Web of Science ®Google Scholar
• Julie Van O. Prescribing for mild-to-moderate psoriasis in adults. Nurse Prescrib. 2012. 10(12):582.
   Google Scholar
• Philipp S, Morcinietz CS, Wallace L, et al. Biologics for the treatment of psoriasis: a systematic review. G Ital Dermatol Venereol. 2007;142(5):567–591.
   Google Scholar
• Urquhart J. The odds of the three nons when an aptly prescribed medicine isn't working: non-compliance, non-absorption, non-response. Br J Clin Pharmacol. 2002;54(2):212–220.
   PubMed Web of Science ®Google Scholar
• Puig L, Carrascosa JM, Belinchon I, et al. Adherence and patient satisfaction with topical treatment in psoriasis, and the use, and organoleptic properties of such treatments: a Delphi study with an expert panel and members of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr. 2013;104(6):488–496.
   PubMedGoogle Scholar
• Augustin M, Peeters P, Radtke M, et al. Cost-effectiveness model of topical treatment of mild to moderate psoriasis vulgaris in Germany. Dermatology. 2007;215(3):219–228.
   PubMed Web of Science ®Google Scholar
• Sabaté E. Adherence to long-term therapies: evidence for action. Geneva, Switzerland: World Health Organization; 2003.
   Google Scholar
• Svendsen MT, Andersen K, Andersen F, et al. Psoriasis patients' experiences concerning medical adherence to treatment with topical corticosteroids. Psoriasis Targ Ther. 2016;6:113–119.
   Web of Science ®Google Scholar
• Fisher EJ, Adams BB. African American and Caucasian patients' vehicle preference for the scalp. J Am Acad Dermatol. 2008;58(2):S46–S47.
   PubMed Web of Science ®Google Scholar
• Hong CH, Papp KA, Lophaven KW, et al. Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO-INSIGHTFUL study. J Eur Acad Dermatol Venereol. 2017;31(11):1876–1883.
   PubMed Web of Science ®Google Scholar
• Felix K, Unrue E, Inyang M, et al. Patients' preferences for different corticosteroid vehicles are highly variable. J Dermatol Treat. 2018;1–18.
   Web of Science ®Google Scholar
• Svendsen MT, Feldmann S, Tiedemann SN, et al. Improving psoriasis patients' adherence to topical drugs: a systematic review. J Dermatolog Treat. 2019;14:1–10.
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Babineau J. Product review: covidence (systematic review software). J Can Health Libr Assoc. 2014;35(2):68–71.
   Google Scholar
• Singh J. Critical appraisal skills programme. J Pharmacol Pharmacother. 2013;4(1):76.
   Google Scholar
• Center for Evidence-based Mangement. Critical Appraisal of a Survey. 2019. Available from: https://www.cebma.org/wp-content/uploads/Critical-Appraisal-Questions-for-a-Survey.pdf
   Google Scholar
• Housman TS, McMichael A, Mellen BG, et al. Use of 0.12% betamethasone valerate foam vs 0.01% fluocinolone acetonide topical oil to treat scalp psoriasis: quantitative assessment of patient preference and treatment efficacy. Cosmetic Dermatol. 2002;15(11):27–30.
   Google Scholar
• Berg M. Emollient creams in the treatment of psoriasis: a study of patient preference. Curr Ther Res. 1994;55(5):598–600.
   Web of Science ®Google Scholar
• Housman TS, Mellen BG, Rapp SR, et al. Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference. Cutis. 2002;70(6):327–332.
   PubMed Web of Science ®Google Scholar
• Iversen L, Jakobsen HB. Patient preferences for topical psoriasis treatments are diverse and difficult to predict. Dermatol Ther (Heidelb). 2016;6(2):273–285.
   PubMed Web of Science ®Google Scholar
• Andreassi L, Giannetti A, Milani M. Efficacy of betamethasone valerate mousse in comparison with standard therapies on scalp psoriasis: an open, multicentre, randomized, controlled, cross-over study on 241 patients. Br J Dermatol. 2003;148(1):134–138.
   PubMed Web of Science ®Google Scholar
• Poyner TF, Menday AP, Williams ZV. Patient attitudes to topical antipsoriatic treatment with calcipotriol and dithranol. J Eur Acad Dermatol Venereol. 2000;14(3):153–158.
   PubMed Web of Science ®Google Scholar
• Abe M, Syuto T, Ishibuchi H, et al. Efficacy of high-concentration tacalcitol ointment in psoriasis vulgaris after changing from other high-concentration vitamin D3 ointments. Dermatol Online J. 2008;14(2):2.
   Google Scholar
• Gual A, Pau-Charles I, Molin S. Topical treatment for scalp psoriasis: comparison of patient preference, quality of life and efficacy for non-alcoholic mometasone emulsion versus calcipotriol/betamethasone gel in daily clinical practice. J Dermatol Treat. 2016;27(3):228–234.
   PubMed Web of Science ®Google Scholar
• Vender R, Gooderham MJ, Guenther LC, et al. Psoriasis patients' preference for an aerosol foam topical formulation. J Eur Acad Dermatol Venereol. 2018;32(11):e400–e401.
   PubMed Web of Science ®Google Scholar
• McMichael AJ. Ethnic hair update: past and present. J Am Acad Dermatol. 2003;48(6):S127–S133.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Housman TS. Patients' vehicle preference for corticosteroid treatments of scalp psoriasis. Am J Clin Dermatol. 2003;4(4):221–224.
   PubMed Web of Science ®Google Scholar
• Stein LF, Sherr A, Solodkina G, et al. Betamethasone valerate foam for treatment of nonscalp psoriasis. J Cutan Med Surg. 2001;5(4):303–307.
   PubMed Web of Science ®Google Scholar